1. Home
  2. SXTP vs EOCN Comparison

SXTP vs EOCN Comparison

Compare SXTP & EOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 60 Degrees Pharmaceuticals Inc.

SXTP

60 Degrees Pharmaceuticals Inc.

HOLD

Current Price

$0.86

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

EOCN

Eocene Ltd. Ordinary Shares

N/A

Current Price

$2.96

Market Cap

3.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SXTP
EOCN
Founded
2010
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
3.6M
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
SXTP
EOCN
Price
$0.86
$2.96
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $3.70
N/A
AVG Volume (30 Days)
★ 119.2K
6.4K
Earning Date
11-12-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 36.77
N/A
EPS
N/A
★ N/A
Revenue
★ $1,005,471.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$70.00
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 65.49
N/A
52 Week Low
$0.34
$2.33
52 Week High
$8.62
$3.80

Technical Indicators

Market Signals
Indicator
SXTP
EOCN
Relative Strength Index (RSI) 39.17 47.58
Support Level $0.84 $3.12
Resistance Level $1.63 $3.80
Average True Range (ATR) 0.09 0.28
MACD -0.01 -0.01
Stochastic Oscillator 12.65 63.08

Price Performance

Historical Comparison
SXTP
EOCN

About SXTP 60 Degrees Pharmaceuticals Inc.

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.

About EOCN Eocene Ltd. Ordinary Shares

Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.

Share on Social Networks: